Dineo Khabele
#148,056
Most Influential Person Now
American obstetrician and researcher
Dineo Khabele's AcademicInfluence.com Rankings
Dineo Khabelemedical Degrees
Medical
#3208
World Rank
#3665
Historical Rank
#497
USA Rank
Gynecology
#4
World Rank
#5
Historical Rank
#1
USA Rank
Obstetrics
#9
World Rank
#21
Historical Rank
#4
USA Rank
Download Badge
Medical
Dineo Khabele's Degrees
- Bachelors Biology Stanford University
- Doctorate Medicine Harvard University
Similar Degrees You Can Earn
Why Is Dineo Khabele Influential?
(Suggest an Edit or Addition)According to Wikipedia, Dineo Khabele is an American obstetrician who is Mitchell and Elaine Yanow Professor of Obstetrics and Gynecology at Washington University in St. Louis. In 2019 Khabele was elected to the American Society for Clinical Investigation.
Dineo Khabele's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- An Interactive Resource to Identify Cancer Genetic and Lineage Dependencies Targeted by Small Molecules (2013) (533)
- Hdac3 is essential for the maintenance of chromatin structure and genome stability. (2010) (320)
- Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology. (2014) (157)
- BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. (2017) (114)
- Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: Implications for therapy (2007) (104)
- Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. (2014) (94)
- Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma (2013) (83)
- The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium (2013) (81)
- Keratinocyte chemoattractant (KC)/human growth-regulated oncogene (GRO) chemokines and pro-inflammatory chemokine networks in mouse and human ovarian epithelial cancer cells (2007) (76)
- Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. (2013) (73)
- The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. (2018) (73)
- Comparative analysis of Napsin A, alpha-methylacyl-coenzyme A racemase (AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma: an immunohistochemical study of 279 ovarian tumours (2015) (60)
- Stimulatory effects of interleukin-induced activation of the hypothalamo-pituitary-adrenal axis on gonadotropin secretion in ovariectomized monkeys replaced with estradiol. (1994) (59)
- Bipolar Tumor-Associated Macrophages in Ovarian Cancer as Targets for Therapy (2018) (59)
- Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. (2003) (54)
- The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells (2011) (50)
- HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. (2014) (44)
- Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer (2015) (43)
- Near-infrared Raman Microspectroscopy Detects High-risk Human Papillomaviruses. (2012) (42)
- Gene expression profile of trisomy 21 placentas: a potential approach for designing noninvasive techniques of prenatal diagnosis. (2002) (41)
- A Call to Action: Black/African American Women Surgeon Scientists, Where are They? (2020) (40)
- Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. (2012) (39)
- The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer (2014) (37)
- Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer (2015) (36)
- Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-δ Signaling in Epithelial Ovarian Cancer (2007) (36)
- Sensitivity of Raman spectroscopy to normal patient variability. (2011) (34)
- Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer (2015) (32)
- TR3 modulates platinum resistance in ovarian cancer. (2013) (32)
- Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. (2015) (31)
- KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine. (2015) (30)
- The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21 (2010) (30)
- Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy (2012) (28)
- Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model (2013) (26)
- Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. (2016) (26)
- Homologous recombination deficiency real-time clinical assays, ready or not? (2020) (26)
- CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes (2020) (24)
- Pharmacologically Increasing Mdm2 Inhibits DNA Repair and Cooperates with Genotoxic Agents to Kill p53-Inactivated Ovarian Cancer Cells (2015) (24)
- Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. (2007) (24)
- Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision? (2015) (24)
- Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. (2013) (23)
- Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer (2020) (23)
- The Role of Race and Gender in the Career Experiences of Black/African American Academic Surgeons (2020) (19)
- Differential Vimentin Expression in Ovarian and Uterine Corpus Endometrioid Adenocarcinomas: Diagnostic Utility in Distinguishing Double Primaries from Metastatic Tumors (2014) (19)
- Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. (2013) (18)
- Aspirin Blocks EGF-stimulated Cell Viability in a COX-1 Dependent Manner in Ovarian Cancer Cells (2013) (18)
- Heated Intraperitoneal Chemotherapy in the Management of Advanced Ovarian Cancer (2018) (18)
- Differential cyclooxygenase expression levels and survival associations in type I and type II ovarian tumors (2018) (18)
- An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. (2012) (18)
- Coenzyme Q10 and lipid-related gene induction in HeLa cells. (2004) (16)
- Early Detection of Treatment-Induced Mitotic Arrest Using Temporal Diffusion Magnetic Resonance Spectroscopy12 (2016) (16)
- Blood type, ABO genetic variants, and ovarian cancer survival (2017) (16)
- Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records (2016) (15)
- A Case of Extrauterine Endometrial Stromal Sarcoma in the Colon Diagnosed Three Decades after Hysterectomy for Benign Disease (2013) (15)
- Examination of Intersectionality and the Pipeline for Black Academic Surgeons. (2022) (12)
- Preferential Effect of Akt2-Dependent Signaling on the Cellular Viability of Ovarian Cancer Cells in Response to EGF (2014) (12)
- Pragmatic trial of an intervention to increase human papillomavirus vaccination in safety-net clinics (2017) (11)
- Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer (2020) (11)
- Tumor necrosis factor-α related gene response to Epothilone B in ovarian cancer (2004) (10)
- Tumor necrosis factor-alpha related gene response to Epothilone B in ovarian cancer. (2004) (10)
- A Perspective on James Marion Sims, MD and Anti-Black Racism in Obstetrics and Gynecology. (2020) (9)
- Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. (2021) (9)
- Pleomorphic liposarcoma of the uterine corpus with focal smooth muscle differentiation. (2011) (9)
- Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer (2019) (9)
- Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer (2021) (8)
- Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer (2020) (8)
- Cardiac tamponade as an unusual presentation of advanced breast cancer in pregnancy. (1999) (8)
- Disparities in ovarian cancer survival at the only NCI-designated cancer center in Kansas (2020) (8)
- Augmented Serum Amyloid A1/2 Mediated by TNF-induced NF-κB in Human Serous Ovarian Epithelial Tumors (2017) (8)
- Increasing Area Deprivation Index negatively impacts ovarian cancer survival. (2021) (7)
- Expression of Keratin 8 and TNF-Related Apoptosis-I Inducing Ligand (TRAIL) in Down Syndrome Placentas. (2008) (7)
- Cervical Cancer Screening and Follow-Up Procedures in Women Age <21 Years Following New Screening Guidelines. (2017) (6)
- Molecular profiles of endometrial cancer tumors among Black patients. (2022) (6)
- Ovarian Volume Measurements in Mice With High‐Resolution Ultrasonography (2007) (6)
- Adrenal Gland Metastasis Is an Unusual Manifestation of Endometrial Cancer (2013) (6)
- 1 TR 3 modulates platinum resistance in ovarian cancer (2013) (5)
- Salpingo-oophorectomy specimens for endometrial cancer staging: a comparative analysis of representative sampling versus whole tissue processing. (2012) (5)
- Evaluation of low-dose intraperitoneal interferon-alpha for palliation of ascites in patients with non-ovarian gynecologic malignancies. (2003) (4)
- Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis (2020) (4)
- Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care (2022) (4)
- Impact of employment and insurance status on distress in gynecologic oncology patients. (2021) (4)
- Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer (2022) (3)
- Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations. (2002) (2)
- Abstract B52: The bromodomain inhibitor JQ1 enhances cisplatin-mediated cytotoxicity in ovarian cancer cells (2013) (2)
- Human papillomavirus vaccination completion rates among gynecological providers: an institutional retrospective review (2019) (2)
- Abstract A42: TR3/NR4A1 as a therapeutic target for ovarian cancer (2018) (2)
- Serum biomarkers for epithelial ovarian carcinoma (2003) (2)
- Abstract 4229: Preliminary results from the Pharmacogenetics Ovarian Cancer Knowledge to Individualize Treatment (POCKIT) study (2018) (2)
- High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer. (2022) (1)
- Abstract 5056: The bromodomain inhibitor JQ1 sensitizes homologous recombination proficient ovarian cancer cells to the PARP inhibitor olaparib (2017) (1)
- Abstract 3457: Rebastinib, a TIE2 antagonist improves chemotherapy response in homologous recombination proficient epithelial ovarian cancer murine models (2022) (1)
- Abstract 3501: Entinostat enhances the efficacy of olaparib in preclinical models of ovarian cancer (2019) (1)
- Detecting Changes in the Cervix with Raman Spectroscopy (2010) (1)
- Abstract 4928: Cyclooxygenase-1 as a target for molecular imaging of high grade serous ovarian cancer (2014) (1)
- Abstract 2235: Circulating microRNA-205 as a potential prognostic biomarker for recurrent ovarian cancer (2019) (1)
- Using Raman Spectroscopy to Detect Cervical Dysplasia in Minority Populations (2010) (1)
- GAS6-AXL inhibition by AVB-500 overcomes resistance to paclitaxel in endometrial cancer by decreasing tumor cell glycolysis. (2022) (1)
- Abstract 626: Bromodomain inhibition in ovarian cancer and the tumor microenvironment to improve PARP inhibitor response (2018) (1)
- Abstract A32: Combination panobinostat and olaparib treatment promotes DNA damage and antitumor immunity in ovarian cancer (2020) (1)
- Ovarian Serous Borderline Tumor Identified in Endometrial Biopsy: A Case Report (2013) (1)
- Results of a Health Education Message Intervention on HPV Knowledge and Receipt of Follow-up Care among Latinas Infected with High-risk Human Papillomavirus (2015) (1)
- Promotion of Gender Equity in Obstetrics and Gynecology: Principles and Practices for Academic Leaders. (2021) (1)
- Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer (2020) (0)
- RAD51 foci as a biomarker predictive of platinum chemotherapy response in ovarian cancer. (2023) (0)
- ROR2-Vangl2 complexes direct ovarian cancer cell motility in response to Wnt5a (265) (2022) (0)
- Errata (1984) (0)
- Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer (2015) (0)
- and expression and platinum resistance in high-grade serous ovarian cancers (2019) (0)
- CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2022) (0)
- Tumor extracelluar hyroxyapatite: a potential biomarker for imaging ovarian cancer (2021) (0)
- EPV004/#360 Inhibition of cancer cell-dependent glycolysis through AVB-500, a selective inhibitor of gas6-axl, in combination with paclitaxel in high-grade endometrial cancer (2021) (0)
- Abstract A15: Noncanonical NF-kappaB signaling is associated with poor ovarian cancer prognosis (2020) (0)
- Abstract B46: Preclinical testing of TR3 activators in cisplatin-resistant ovarian cancer (2013) (0)
- Abstract C79: The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly (ADP-ribose) polymerase inhibitor olaparib (2016) (0)
- Abstract PO047: AVB-500, a receptor tyrosine kinase AXL inhibitor, improves response to olaparib in uterine serous cancer (2021) (0)
- Persistent inequities in access to and continuity of gynecologic oncology care during the COVID-19 pandemic (052) (2022) (0)
- A Clinicopathologic Analysis of Galectin-3 Expression in 209 Ovarian Carcinomas (2012) (0)
- Patterns of BRD4 protein expression in advanced stage high-grade serous ovarian cancers (2020) (0)
- 26 Pharmacologic inhibition of discoidin domain receptor 2 (DDR2) sensitizes homologous recombination proficient ovarian cancer models to treatment with olaparib (2022) (0)
- Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173) (2022) (0)
- Pharmacologic inhibition of discoidin domain Receptor 2 (DDR2) sensitizes homologous recombination proficient ovarian cancer models to treatment with olaparib (245) (2022) (0)
- Abstract 982: Increasing HPV vaccine utilization among Hispanic girls to reduce cervical cancer disparities (2010) (0)
- Wnt5a influences the directional displacement of ovarian cancer cells (2021) (0)
- Abstract C40: Investigating histone deacetylase 3 expression in ovarian cancer cells (2014) (0)
- Abstract NT-088: PROGNOSTIC SIGNIFICANCE OF NR4A1/TR3 EXPRESSION IN OVARIAN CANCER (2019) (0)
- EPV007/#582 DNA damage repair is altered by inhibition of discoidin domain receptor 2 (DDR2) through metabolic rewiring in homologous-recombination proficient ovarian cancer models (2021) (0)
- Title: KRAS genomic status predicts the sensitivity of ovarian cancer cells to decitabine Running Title: KRAS status predicts sensitivity to decitabine in ovarian cancer Authors: Stewart ML, Tamayo (2015) (0)
- An orthotopic model of fallopian tube serous carcinoma. (2011) (0)
- Abstract PO045: Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer (2021) (0)
- Abstract 1016: Combination low dose 5-azacytidine (AZA) and romidepsin (FK228) therapy re-sensitizes ovarian cancer cells to cisplatin. (2013) (0)
- Socioeconomic disparities in distress and coping in gynecologic oncology patients (568) (2022) (0)
- Abstract 294: A novel cancer therapeutic strategy: inducing cytotoxic functions in tumor-associated macrophages (2015) (0)
- Detecting Cervical Dysplasia in Minority Populations using Raman Spectroscopy (2011) (0)
- Geographic distance greater than 50 miles is associated with better overall survival for ovarian cancer patients treated at a frontier state NCI-designated cancer center (2020) (0)
- Adjuvant chemotherapy and radiation therapy with the “sandwich” method for endometrial cancer: an institutional analysis (2021) (0)
- A Race-Conscious Analysis of the Use of Transvaginal Ultrasonography in the Evaluation of Postmenopausal Bleeding. (2021) (0)
- Romidepsin (FK228) combined with cisplatin enhances DNA damage response phosphorylation of gamma H2AX in ovarian cancer cells (2012) (0)
- Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer (2018) (0)
- Abstract 5291: A preclinical model for investigation of nuclear factor-kappa B inhibitors in ovarian cancer (2011) (0)
- Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer (2022) (0)
- Gynecologic oncology patients who are unemployed and underinsured face high distress that extends beyond financial toxicity (2021) (0)
- Abstract C19: Assessing metformin use and ovarian cancer survival from electronic medical records (2016) (0)
- Protein expression by immunohistochemistry is associated with and gene amplification (2022) (0)
- 27 Entinostat restores responsiveness to olaparib in ID8 TP53 null and ID8 TP53 null/BRCA2 null mouse ovarian cancer cell lines (2022) (0)
- Combining molecular subtype and traditional histo-pathologic tumor classifications to predict survival in patients with endometrioid or serous endometrial cancers (221) (2022) (0)
- Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer (2021) (0)
- Incidental placenta increta at the time of prophylactic hysterectomy for Lynch syndrome: Insights into individualized decision-making and surgical timing (2015) (0)
- Abstract B16: Resources for research: Identification and validation of ovarian cancer cases from the Synthetic Derivative (2013) (0)
- Abstract A15: The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. (2016) (0)
- Current issues regarding tamoxifen and the genital tract: a review (2003) (0)
- A Nomogram Predicting Early Cervical Cancer Distant Recurrence. (2021) (0)
- High visceral fat to subcutaneous fat adiposity ratios portend a poor prognosis in patients with endometrial cancer (2021) (0)
- Abstract 4214: Assessment of early antimitotic treatment response in ovarian cancer using temporal diffusion spectroscopy (2016) (0)
- O462 A no‐cost breast cancer screening program promotes cervical cancer screening services to an underserved population of women (2009) (0)
- Abstract B17: Type 2 diabetes, metformin, and ovarian cancer survival: An analysis of tumor registry and electronic medical record data. (2016) (0)
- ROR2 can function independent of tyrosine kinase activity to promote ovarian cancer metastasis (264) (2022) (0)
- Changes in Cervical Cancer Screening and Follow-Up in Women Under Age 21 Following New Screening Guidelines [11M] (2016) (0)
- Promoting cervical cancer screening services through a breast cancer screening program (2007) (0)
- Abstract 2985: DNA-damage related histone marks can distinguish the anti-tumor effects of established and novel histone deacetylase inhibitors in ovarian cancer cells (2010) (0)
- Abstract 4954: Opposing effects of the NF-kappaB inhibitor thymoquinone in a syngeneic mouse model of ovarian cancer. (2013) (0)
- Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer (2021) (0)
- Correlation of CCNE1 copy number levels with molecular profiles and outcomes for high grade serous ovarian and endometrial cancer (121) (2022) (0)
- Abstract GMM-046: CCNE1 AND BRD4 EXPRESSION AND PLATINUM RESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCERS (2019) (0)
- NR4A1 inhibition as a novel strategy to sensitize homologous recombination-proficient ovarian cancer to PARP inhibitors (2019) (0)
- Preventing ovarian cancer cell metastasis through inhibition of discoidin domain receptor 2 (DDR2) in the tumor microenvironment: a metabolomic analysis (2021) (0)
- Abstract B04: The bromodomain inhibitor INCB054329 enhances olaparib response in ovarian cancer cells by reducing homologous recombination efficiency (2018) (0)
- Abstract POSTER-BIOL-1350: Dissecting cellular and molecular consequences of disrupting cyclooxygenase-1 activity in ovarian cancer (2015) (0)
- Abstract NTOC-092: THE BROMODOMAIN INHIBITOR JQ1 SENSITIZES HOMOLOGOUS RECOMBINATION PROFICIENT OVARIAN CANCER CELLS TO THE PARP INHIBITOR OLAPARIB (2017) (0)
- Abstract 1573: Non-canonical NF-kappaB signaling in the tumor microenvironment in relation to ovarian cancer survival (2019) (0)
- Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids. (2023) (0)
- Abstract 3404: Thrombocytosis and epithelial ovarian cancer survival: relevant time frame of platelet count measurement and diagnostic threshold for thrombocytosis (2016) (0)
- Clinical Trials and Translational Applications in Cancer Therapy (2009) (0)
- Abstract PO002: Inducing homologous recombination deficiency in uterine serous cancer (USC) using AVB-500, a receptor tyrosine kinase AXL inhibitor (2021) (0)
- Inducing homologous recombination deficiency using AVB500, a receptor tyrosine kinase AXL inhibitor in uterine serous cancer (USC) (2021) (0)
- Low quality of life and activity levels persist in obese endometrial cancer survivors despite participation in a behavioral weight loss intervention (2021) (0)
- Reducing paclitaxel hypersensitivity reactions in gynecologic oncology patients (521) (2022) (0)
- Molecular and Cellular Pathobiology TR 3 Modulates Platinum Resistance in Ovarian Cancer (2013) (0)
- Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records (2016) (0)
- Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays. (2023) (0)
- Abstract 4711: Modulation of NFκ-B signaling to optimize antitumor characteristics in macrophages (2018) (0)
- Abstract 3654: Olaparib combined with entinostat exerts differential effects on tumor-associated macrophages in tumors compared to ascites in syngeneic HR-proficient murine models of ovarian cancer (2023) (0)
- Erratum to: “Expression of Keratin 8 and TNF-Related Apoptosis-I Inducing Ligand (TRAIL) in Down Syndrome Placentas” [Placenta 2008;29(4):382–4] (2008) (0)
- AVB-500, a receptor tyrosine kinase AXL inhibitor, in combination with olaparib improves response in uterine serous cancer (2021) (0)
- Abstract 5306: IRAK1: A novel TOLLway to target ovarian cancer (2022) (0)
- Abstract MIP-046: BLOOD TYPE, ABO GENETIC VARIANTS, AND OVARIAN CANCER SURVIVAL (2017) (0)
- Abstract B81: The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to the cyclin-dependent kinase 2 inhibitor dinaciclib. (2016) (0)
- Abstract TMIM-085: BROMODOMAIN INHIBITION IN OVARIAN CANCER AND THE TUMOR MICROENVIRONMENT (2019) (0)
- Abstract 1379: Entinostat induces PARPi sensitivity across multiple ovarian cancer models (2020) (0)
- Community access to primary care is an important geographic disparity among ovarian cancer patients undergoing cytoreductive surgery (2022) (0)
- Comparison of three testing strategies for germline genetic testing for homologous recombination deficiency mutations in women with epithelial ovarian cancer (198) (2022) (0)
- Abstract 795: Entinostat restores responsiveness to Olaparib in ID8 TP53 null and ID8 TP53 null/BRCA2 null mouse ovarian cancer cell lines (2022) (0)
- AVB-500, a selective inhibitor of GAS6-AXL, shows improved therapeutic efficacy in combination with paclitaxel in uterine serous carcinoma (2021) (0)
- Abstract 4730: The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP-ribose polymerase inhibitor olaparib (2016) (0)
- Abstract 2429: Tumor and stromal AXL expression regulate ovarian cancer metastasis (2022) (0)
- Abstract A63: The importance of cyclooxygenase 1 and 2 expression in ovarian cancer survival: Notable differences by histologic subtype. (2016) (0)
- Abstract LB164: Entinostat restores sensitivity to olaparib in two in vitro models of PARPi resistant ovarian cancer cells (2023) (0)
- Abstract POSTER-TECH-1103: Aspirin, NSAIDS, and ovarian cancer survival from electronic medical records (2015) (0)
- Discoidin Domain Receptor 2 (DDR2) expression in combination with mutation status is predictive of survival in patients with ovarian cancer (2021) (0)
- Overall survival with or without adjuvant radiotherapy among different molecular subtypes of endometrial cancer (211) (2022) (0)
- Germline and somatic genetic testing trends among women with epithelial ovarian cancer (197) (2022) (0)
- Nucleophosmin expression in ovarian cancer. (2012) (0)
- Targeting PI3K/AKT signaling and the TR3/NR4A1 receptor in ovarian cancer (2014) (0)
- Abstract B70: Targeted activation of macrophages to limit ovarian cancer progression. (2016) (0)
- Abstract B6: Social marketing intervention to increase HPV vaccine utilization among Hispanic girls: Preliminary data (2010) (0)
- Cognitive behavioral therapy for weight management in gynecologic oncology (288) (2022) (0)
- Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer (2021) (0)
- Abstract B37: The histone deacetylase inhibitor panobinostat sensitizes cyclin E-amplified ovarian cancer cells to poly ADP ribose polymerase inhibitors via E2F1 downregulation. (2016) (0)
- Increasing sensitivity to olaparib through inhibition of discoidin domain receptor 2 (DDR2) in homologous-recombination proficient ovarian cancer models (2021) (0)
- Expression of p52, a non-canonical NF-kappaB transcription factor, is associated with poor ovarian cancer prognosis (2020) (0)
- The Dobbs v Jackson Women's Health Organization Supreme Court Decision-Concerns, Challenges, and Consequences for Health Care. (2022) (0)
- The pattern of H3K56 acetylation expression in ovarian cancer (2011) (0)
- Olaparib and suberoylanilide hydroxamic acid (SAHA): A novel combination for targeting DNA damage response pathways in ovarian cancer cells (2012) (0)
- Abstract 346: Aspirin blocks EGF responsiveness in ovarian cancer cells (2010) (0)
- Characterization of the mutational landscape of high-grade serous ovarian tumors before and after neo-adjuvant chemotherapy (267) (2022) (0)
- Abstract 2068: Cyclooxygenase-1 gene expression contributes to multiple oncogenic pathways in high grade serous ovarian cancer (2015) (0)
- AVB-500, a selective inhibitor of GAS6-AXL, in combination with paclitaxel alters uterine serous cancer cell metabolism (2021) (0)
- Abstract 320: Investigating the patterns of nuclear factor-kappa B activity in the host-tumor microenvironment during ovarian cancer progression (2012) (0)
- Silencing ROR2 inhibits metastatic behavior of ovarian cancer cells (2021) (0)
This paper list is powered by the following services:
Other Resources About Dineo Khabele
What Schools Are Affiliated With Dineo Khabele?
Dineo Khabele is affiliated with the following schools:
